Research
Albumin-bound paclitaxel–induced stromal reprogramming drives resistance to neoadjuvant chemotherapy in patients with pancreatic cancer
Science · By Haorui Li, Xi Ma, Xupeng Hou, Xugang Sun, Xiang He, Kejia Liu, Henan Cao, Libo Wang, Yibo Dou, Jie Yu, Bin Wang, Tianxing Zhou, Chuntao Gao, Jun Yu, Yongjie Xie, Yukuan Feng, Tiansuo Zhao & Jihui Hao ·
The Brief
- A study in Science Translational Medicine reports that albumin-bound paclitaxel can induce stromal reprogramming in pancreatic tumours.
- The stromal reprogramming is linked to resistance to neoadjuvant chemotherapy in patients with pancreatic cancer.
- The paper was published in Volume 18, Issue 875 of the journal in November 2026.
Why it matters
It points to the tumour stroma, not only the cancer cells, as a possible driver of poor response to neoadjuvant chemotherapy, which could inform how treatment regimens are designed for pancreatic cancer patients.
Who’s affected
- pancreatic cancer researchers and oncologists
- clinicians who prescribe neoadjuvant chemotherapy
- #pancreatic cancer
- #chemotherapy resistance
- #paclitaxel
- #tumor stroma
- #neoadjuvant therapy
Science Translational Medicine, Volume 18, Issue 875 , November 2026.
Timeline
Study published in Science Translational Medicine
science.org
Albumin-bound paclitaxel–induced stromal reprogramming drives resistance to neoadjuvant chemotherapy in patients with pancreatic cancer